Objective: To evaluate the efficacy and safety of sequential prophylaxis with letermovir injection and tablets for Cytomegalovirus(CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Methods: The study included 18 patients who completed allo-HSCT at the Blood Disease Hospital, Chinese Academy of Medical Sciences from December 2023 to March 2024. Letermovir injection was initiated on day 0 post-transplant, followed by a switch to letermovir tablets for sequential prophylaxis up to day 90. The primary outcome was the CMV breakthrough rate at 90 days post-transplant, and the second outcomes were the incidence of viral infections such as EBV and the status of hematopoietic reconstitution.

Results: At 90 days post-transplant, among the 18 allo-HSCT patients who received sequential prophylaxis with letermovir injection and tablets, no CMV infection was observed in all patients, resulting in a CMV infection breakthrough rate of 0%. Four patients had EB virus (EBV) viremia (22.22%), of which one patient developed PTLD (5.6%). The median time for neutrophil engraftment was 15 (11-18) days; no related liver and kidney function damage was observed during the medication process.

Conclusion: Preliminary research results indicate that sequential prophylaxis with letermovir injection and tablets is safe and effective for post-allo-HSCT CMV infection.

Disclosures

No relevant conflicts of interest to declare.

This content is only available as a PDF.
2024
Sign in via your Institution